Title:
METHODS OF REDUCING RISK OF PROSTATE CANCER PROGRESSION
Document Type and Number:
WIPO Patent Application WO/2022/181818
Kind Code:
A1
Abstract:
This disclosure provides methods of reducing the risk of prostate cancer progression in patients with a histologically proven prostate cancer characterized as low or intermediate risk for which no other treatment for prostate cancer is indicated. The method comprises administering enzalutamide as a monotherapy in an amount and for a period of time clinically proven effective in reducing the risk of prostate cancer progression in a control population of patients under active surveillance and having histologically proven prostate cancers characterized as low or intermediate risk for which no other treatment for prostate cancer is indicated.
Inventors:
HAIRSTON JOHN (US)
BROWN BRUCE (US)
BROWN BRUCE (US)
Application Number:
PCT/JP2022/008383
Publication Date:
September 01, 2022
Filing Date:
February 28, 2022
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
A61K31/4164; A61P35/00
Other References:
ANONYMOUS: "History of Changes for Study: NCT02799745 A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)", CLINICALTRIALS.GOV, NCT02799745, 27 November 2020 (2020-11-27), XP055961868
NEAL D. SHORE, SRINIVAS VOURGANTI, JONATHAN L. SILBERSTEIN, BRUCE A. BROWN, SAMUEL WILSON, COURTNEY M.P. HOLLOWELL: "A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT)", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 35, no. 15, 1 January 2017 (2017-01-01), US , XP009539223, ISSN: 0732-183X
MOYAD MARK A, SCHOLZ MARK: "Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial", RESEARCH AND REPORTS IN UROLOGY, vol. 6, 16 July 2014 (2014-07-16), pages 71 - 77, XP055961871, DOI: 10.2147/RRU.S63136
NEAL D. SHORE, SRINIVAS VOURGANTI, JONATHAN L. SILBERSTEIN, BRUCE A. BROWN, SAMUEL WILSON, COURTNEY M.P. HOLLOWELL: "A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT)", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 35, no. 15, 1 January 2017 (2017-01-01), US , XP009539223, ISSN: 0732-183X
MOYAD MARK A, SCHOLZ MARK: "Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial", RESEARCH AND REPORTS IN UROLOGY, vol. 6, 16 July 2014 (2014-07-16), pages 71 - 77, XP055961871, DOI: 10.2147/RRU.S63136
Attorney, Agent or Firm:
NAKAMURA Yukitaka et al. (JP)
Download PDF: